1. Home
  2. UGRO vs SNGX Comparison

UGRO vs SNGX Comparison

Compare UGRO & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo urban-gro Inc.

UGRO

urban-gro Inc.

HOLD

Current Price

$0.29

Market Cap

3.0M

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.42

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UGRO
SNGX
Founded
2014
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
13.8M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
UGRO
SNGX
Price
$0.29
$1.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$6.00
AVG Volume (30 Days)
13.7M
455.1K
Earning Date
02-17-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$59,985,138.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$28.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$1.09
52 Week High
$1.19
$6.23

Technical Indicators

Market Signals
Indicator
UGRO
SNGX
Relative Strength Index (RSI) 47.63 48.55
Support Level $0.27 $1.31
Resistance Level $0.38 $1.45
Average True Range (ATR) 0.07 0.10
MACD -0.00 -0.00
Stochastic Oscillator 19.54 43.43

Price Performance

Historical Comparison
UGRO
SNGX

About UGRO urban-gro Inc.

Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: